I reported previously (see here) on BiomX. The Israeli biotech has now partnered with Janssen – the therapy R&D arm of Johnson & Johnson. BiomX’s XMarker microbiome-based platform will be used to classify responders to inflammatory bowel disease (IBD) therapies.
https://en.globes.co.il/en/article-israeli-microbiome-co-biomx-teams-with-jj-1001264660